Insider Transactions Reported by 17 Insiders of Akero Therapeutics, Inc.

Symbol
AKRO on Nasdaq
Location
South San Francisco, CA

Insiders trading volume in the past year

Akero Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Skorpios Trust Former 10% owner $2,012,175 01 Dec 2022
Patrick Lamy Senior VP, Commercial Strategy $0 -$1,100,720 -100% 09 Dec 2025
Andrew Cheng President and CEO, Director $0 -$12,026,783 -100% 09 Dec 2025
G. Walmsley Graham Director $0 +$8,787,921 09 Dec 2025
William Richard White Chief Financial Officer $0 -$299,700 -100% 09 Dec 2025
Catriona Yale Chief Development Officer $0 -$3,051,789 -100% 09 Dec 2025
Scott A. Gangloff Chief Technology Officer $0 -$46,504 -100% 09 Dec 2025
Seth Loring Harrison Director $0 09 Dec 2025
Tomas J. Heyman Director $0 09 Dec 2025
Timothy Rolph Chief Scientific Officer $0 -$6,244,070 -100% 09 Dec 2025
Jane Henderson Director $0 -$142,371 -100% 09 Dec 2025
Jonathan Young Chief Operating Officer $0 -$4,280,292 -100% 09 Dec 2025
Mark Iwicki Director $0 09 Dec 2025
Yuan Xu Director $0 09 Dec 2025
Chou Judy Director $0 09 Dec 2025
ATP Life Science Ventures, L.P. 10%+ Owner 28 Jun 2021
Kevin Bitterman Director 01 Jun 2021

Recent Insider Transactions by Companies or Individuals for Akero Therapeutics, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.